'Tentative' FDA Nod to Trokendi XR for Migraine Prevention

Pauline Anderson

Disclosures

August 22, 2016

The US Food and Drug Administration (FDA) has granted tentative approval to expand the label for an extended-release formulation of topiramate (Trokendi XR, Supernus Pharmaceuticals), approved for epilepsy, to include prophylaxis of migraine headache in adults, the company announced.

The approval of the company's Supplemental New Drug Application (sNDA) is tentative because while the FDA has determined that the drug meets all the required quality, safety, and efficacy standards for approval, it is subject to pediatric exclusivity, which expires March 28, 2017, the company reports in a press release August 22.

Final approval may not be made effective until this exclusivity period has expired, the release notes. 

"We will continue to work with the FDA to gain final approval upon the expiration of pediatric exclusivity," said Jack Khattar, president and chief executive officer of Supernus Pharmaceuticals, in a press release. "We are prepared and ready to launch the migraine indication upon receiving full FDA approval." 

Supernus further announced that the FDA has granted final approval to expand the label for Trokendi XR for monotherapy treatment of partial-onset seizures to include patients 6 years and older, rather than 10 years and older, as well as adults. 

In addition to now being indicated for initial monotherapy in patients 6 years and older with partial-onset or primary generalized tonic-clonic seizures, Trokendi XR is also indicated as adjunctive therapy in these patients and in those 6 years of age and older with seizures associated with Lennox-Gastaut syndrome.

The product is available in 25-mg, 50-mg, 100-mg, and 200-mg extended-release capsules.

Another extended-release topiramate (Qudexy, Upsher-Smith) received FDA approval as an initial monotherapy in patients as young as 2 years with partial-onset seizures or primary generalized tonic-clonic seizures in June 2015.

It was previously approved in March 2014 for use as initial monotherapy in patients 10 years of age and older with partial-onset seizures or primary generalized tonic-clonic seizures, and as adjunctive therapy in patients 2 years of age or older with partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....

Recommendations